Vaccination response to tetanus toxoid and 23-valent pneumococcal vaccines following administration of a single dose of abatacept: a randomized, open-label, parallel group study in healthy subjects

Table 2 Abatacept serum concentration levels determined 14 and 28 days after vaccination

Group	Baseline (μg/ml)	14 days after vaccination (μg/ml)	28 days after vaccination (μg/ml)
Group A^a (vaccines alone on day 1)	N/A	N/A	N/A
Group B^b (vaccines 2 weeks before abatacept)	N/A	N/A	28.6 (26)
Group C (vaccines 2 weeks after abatacept)	N/A	12.5 (19)	6.1 (20)
Group D (vaccines 8 weeks after abatacept)	N/A	1.3 (56)	0.4 (106)

Data presented as the geometric means (percentage of the coefficient of variation. N/A: not applicable. ^aSubjects in Group A did not receive abatacept. ^bSubjects in Group B received abatacept at 14 days (serum concentration taken pre-abatacept dosing).

ISSN: 1478-6362